CSRC Event Details

“New Advances in the Assessment of Drug-Induced Arrhythmias and the Comprehensive In Vitro Proarrhythmia Assay (CiPA)”

Monday, May 21 – Tuesday, May 22, 2018


Rates:
Academic/Professional Societies/Non-Profits: $250 (total cost for both days)
Commercial Industry Members: $700 (total cost for both days)
Commercial/Industry Non-Members: $1650 (total cost for both days)
Government: Complimentary

Location: Kellogg Conference Hotel | 800 Florida Ave. NE Washington, D.C. 20002

On-site registration available. 
Slides & AgendaMeeting Logistics | Driving Directions | Walking Directions | Map: 6th Street Parking Garage 


“Defining the Clinical and Regulatory Landscape for Cardiogenic Shock”

Friday, September 7, 2018

Rates:
Academic/Professional Societies/Non-Profits: $200
Commercial Industry Members: $650
Commercial/Industry Non-Members: $1250
Government: Complimentary

Location and Hotel Accommodations: Grand Hyatt Hotel | 1000 H Street |Washington, D.C.

Registration site: https://events.duke.edu/csrc-sept-2018 

Draft agenda


CSRC-DIA Mobile Technologies Think Tank:
"Use of Mobile Technologies in Clinical Trials for Assessment of Cardiovascular Endpoints”

Wednesday, October 10, 2018

Rates:
Academic/Professional Societies/Non-Profits: $200
Commercial Industry Members: $650
Commercial/Industry Non-Members: $1250
Government: Complimentary

Location: ACC Heart House | 2400 N St. NW, Washington, DC 20037

Hotel Accommodations: Fairmont Washington, D.C. | 2401 M St. NW, Washington, D.C. 20037
To book your sleeping room accommodations at our group rate, click here. Rooms must be booked by September 18, 2018.

Registration site: https://events.duke.edu/csrc-thinktank18

There is an increasing number of health care apps and wearable technologies – many of which are purported to be able to assess  cardiovascular safety in clinical trials.  Can the promised efficiencies of mobile technology also translate to efficiencies in clinical trials?  This think tank is designed to elucidate the requirements which need to be met in order for these mobile technologies to support  cardiovascular  endpoints.  The think tank has leaders from academics, FDA and industry and will explore device features, patient features, endpoint validation and regulatory considerations.


Stay tuned for more information on the following events:

  • October 2018: “Evaluation of Heart Failure as an Off-Target Event in Development of Diabetes and other Non-cardiac Drugs”
  • January 2019: “Driving Efficiencies in Clinical Trials through the use of Cardiac Biomarkers”